IR@PKUHSC  > 北京大学第三临床医学院
学科主题临床医学
Circulating miR-19a and miR-205 in Serum May Predict the Sensitivity of Luminal A Subtype of Breast Cancer Patients to Neoadjuvant Chemotherapy with Epirubicin Plus Paclitaxel
Li, Qian1,2,3,7; Liu, Mei2,3,4,5; Ma, Fei1,2,3; Luo, Yang1,2,3; Cai, Ruigang1,2,3; Wang, Liming2,3,6; Xu, Ningzhi2,3,4,5; Xu, Binghe1,2,3
刊名PLOS ONE
2014-08-19
DOI10.1371/journal.pone.0104870
9期:8
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Multidisciplinary Sciences
资助者National Natural Science Foundation ; Beijing Hope Run Special Fund ; Capital Clinical Feature Applied Research Fund ; National Natural Science Foundation ; Beijing Hope Run Special Fund ; Capital Clinical Feature Applied Research Fund
研究领域[WOS]Science & Technology - Other Topics
关键词[WOS]MICRORNA EXPRESSION ; PROGNOSTIC-SIGNIFICANCE ; ADJUVANT CHEMOTHERAPY ; IDENTIFICATION ; RESISTANCE ; CELLS ; GENE ; TRASTUZUMAB ; PATHWAY ; MARKERS
英文摘要

Background: The luminal A subtype of breast cancer has a good prognosis and is sensitive to endocrine therapy but is less sensitive to chemotherapy. It is necessary to identify biomarkers to predict chemosensitivity and avoid over-treatment. We hypothesized that miRNAs in the serum might be associated with chemosensitivity.

Methods: Sixty-eight breast cancer patients received neoadjuvant chemotherapy with epirubicin plus paclitaxel. The serum of the patients was collected before chemotherapy and stored at -80 degrees C. The samples were classified into two groups in term of the chemosensitivity. We identified the differential expression patterns of miRNAs between the chemotherapy sensitive and resistant groups using microRNA profiling. Four miRNAs that were differentially expressed between the two groups were further validated in another 56 samples. We created a model fitting formula and a receiver operating characteristics (ROC) curve using logistic regression analysis to evaluate the prediction potency.

Results: We identified 8 miRNAs differentially expressed between the two groups: 6 miRNAs were up-regulated, and 2 miRNAs were down-regulated in the resistant group compared with the sensitive group. The expression of miR-19a and miR-205 were determined to have significant differences between the two groups (P<0.05). A predictive model of these two miRNAs was created by the logistic regression analysis. The probability of this model was 89.71%. Based on the ROC curve, the specificity was 75.00%, and the sensitivity was 81.25%.

Conclusions: The combination of miR-19a and miR-205 in the serum may predict the chemosensitivity of luminal A subtype of breast cancer to epirubicin plus paclitaxel neoadjuvant chemotherapy.

语种英语
所属项目编号81372830 ; LC2013L09 ; Z141107002514010
资助者National Natural Science Foundation ; Beijing Hope Run Special Fund ; Capital Clinical Feature Applied Research Fund ; National Natural Science Foundation ; Beijing Hope Run Special Fund ; Capital Clinical Feature Applied Research Fund
WOS记录号WOS:000340742100050
引用统计
被引频次:19[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/58013
专题北京大学第三临床医学院
作者单位1.Chinese Acad Med Sci, Inst Canc, Dept Med Oncol, Beijing 100021, Peoples R China
2.Chinese Acad Med Sci, Canc Hosp, Beijing 100021, Peoples R China
3.Peking Union Med Coll, Beijing 100021, Peoples R China
4.Chinese Acad Med Sci, Inst Canc, Lab Cell & Mol Biol, Beijing 100021, Peoples R China
5.Chinese Acad Med Sci, Inst Canc, State Key Lab Mol Oncol, Beijing 100021, Peoples R China
6.Chinese Acad Med Sci, Inst Canc, Dept Abdominal Surg, Beijing 100021, Peoples R China
7.Peking Univ, Hosp 3, Dept Tumor Chemotherapy & Radiat Sickness, Beijing 100871, Peoples R China
推荐引用方式
GB/T 7714
Li, Qian,Liu, Mei,Ma, Fei,et al. Circulating miR-19a and miR-205 in Serum May Predict the Sensitivity of Luminal A Subtype of Breast Cancer Patients to Neoadjuvant Chemotherapy with Epirubicin Plus Paclitaxel[J]. PLOS ONE,2014,9(8).
APA Li, Qian.,Liu, Mei.,Ma, Fei.,Luo, Yang.,Cai, Ruigang.,...&Xu, Binghe.(2014).Circulating miR-19a and miR-205 in Serum May Predict the Sensitivity of Luminal A Subtype of Breast Cancer Patients to Neoadjuvant Chemotherapy with Epirubicin Plus Paclitaxel.PLOS ONE,9(8).
MLA Li, Qian,et al."Circulating miR-19a and miR-205 in Serum May Predict the Sensitivity of Luminal A Subtype of Breast Cancer Patients to Neoadjuvant Chemotherapy with Epirubicin Plus Paclitaxel".PLOS ONE 9.8(2014).
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Li, Qian]的文章
[Liu, Mei]的文章
[Ma, Fei]的文章
百度学术
百度学术中相似的文章
[Li, Qian]的文章
[Liu, Mei]的文章
[Ma, Fei]的文章
必应学术
必应学术中相似的文章
[Li, Qian]的文章
[Liu, Mei]的文章
[Ma, Fei]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。